T-cell large granular lymphocytic leukemia: treatment experience with fludarabine

dc.citation.epage748pt_BR
dc.citation.issue7pt_BR
dc.citation.spage745pt_BR
dc.citation.volume67pt_BR
dc.creatorCosta, Renata Oliveira
dc.creatorBellesso, Marcelo
dc.creatorChamone, Dalton Alencar Fischer
dc.creatorRuiz, Milton Artur
dc.creatorHallack Neto, Abrahão Elias
dc.creatorAldred, Vera Lucia
dc.creatorPereira, Juliana
dc.date.accessioned2018-12-21T13:10:05Z
dc.date.available2018-12-19
dc.date.available2018-12-21T13:10:05Z
dc.date.issued2012-07
dc.description.abstractOBJECTIVES: The aim of this retrospective study was to investigate the results of T-cell large granular lymphocytic leukemia treatment with fludarabine by assessing the complete hematologic response, the complete molecular response, progression-free survival, and overall survival. METHODS: We evaluated the records of six patients with T-cell large granular lymphocytic leukemia who were treated with fludarabine as a first-, second-, or third-line therapy, at a dose of 40 mg/m2, for three to five days per month and 6 to 8 cycles. RESULTS: Of the six patients investigated with T-cell large granular lymphocytic leukemia who were treated with fludarabine, five (83.3%) were female, and their median age was 36.5 years (range 18 to 73). The median lymphocyte level was 3.4x109/L (0.5 to 8.9). All patients exhibited a monoclonal T-cell receptor gamma gene rearrangement at diagnosis. Two (33.3%) patients received fludarabine as first-line treatment, two (33.3%) for refractory disease, one (16.6%) for relapsed disease after the suspension of methotrexate treatment dueto liver toxicity, and one (16.6%) due to dyspesia. A complete hematologic response was achieved in all cases, and a complete molecular response was achieved in five out six cases (83.3%). During a mean follow-up period of 12 months, both the progression-free survival and overall survival rates were 100%. CONCLUSION: T-cell large granular lymphocytic leukemia demonstrated a high rate of complete hematologic and molecular response to fludarabine, with excellent compliance and tolerability rates. To confirm our results in this rare disease, we believe that fludarabine should be tested in clinical trials as a first-line treatment for T-cell large granular lymphocytic leukemia.pt_BR
dc.description.resumo-pt_BR
dc.identifier.doihttp://dx.doi.org/10.6061/clinics/2012(07)07pt_BR
dc.identifier.urihttps://repositorio.ufjf.br/handle/ufjf/8366
dc.languageengpt_BR
dc.publisher-pt_BR
dc.publisher.countryBrasilpt_BR
dc.publisher.initials-pt_BR
dc.relation.ispartofClinicspt_BR
dc.rightsAcesso Abertopt_BR
dc.subjectFludarabinept_BR
dc.subjectTreatmentpt_BR
dc.subjectLarge Granular Lymphocyte Leukemiapt_BR
dc.subject.cnpq-pt_BR
dc.titleT-cell large granular lymphocytic leukemia: treatment experience with fludarabinept_BR
dc.typeArtigo de Periódicopt_BR

Files

Original bundle

Now showing 1 - 1 of 1
Loading...
Thumbnail Image
Name:
T-cell large granular lymphocytic leukemia.pdf
Size:
145.69 KB
Format:
Adobe Portable Document Format

License bundle

Now showing 1 - 1 of 1
Loading...
Thumbnail Image
Name:
license.txt
Size:
2.15 KB
Format:
Item-specific license agreed upon to submission
Description: